MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/acn3.52252

Медицинская библиотека · Annals of clinical and translational neurology · 2024

Neuromuscular transmission deficits in patients with CMT and ClC-1 inhibition in CMT animal models.

Grønnebæk Thomas Skjærlund, Haahr-Lillevang Helga, Skov Martin, Kelly Kristina, Kerr Nathan R, Viteri Jose A, Jaworek Andrea, Bartlett Amy, Bold Jane, Hutchison John, Quiroz Jorge, Tankisi Hatice, Pedersen Thomas Holm, Andersen Henning, Arnold William David

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

OBJECTIVE

Charcot-Marie Tooth (CMT) is a hereditary neuropathy characterized by muscle weakness and fatigue with no approved therapies. Preclinical studies implicate neuromuscular junction (NMJ) transmission deficits in muscle dysfunction in CMT. This study aimed to evaluate NMJ function in patients with CMT types 1 and 2, and to determine whether enhancing NMJ transmission can improve muscle function in preclinical CMT models.

METHODS

First, an observational study involving single fiber electromyography (SFEMG) and clinical testing in patients with CMT 1 and 2 and healthy controls (HC) was conducted. Next, preclinical studies examined muscle function, specifically nerve-stimulated muscle force after partially inhibiting ClC-1 chloride channels with the novel small molecule NMD670.

RESULTS

Twenty-one CMT patients (46.4 ± 14.4 years) and 10 HC (43.3 ± 12.7 years) were enrolled. SFEMG jitter (NMJ variability) was higher [median (range)] in the CMT patients [56 μs (35; 197 μs)] vs. HC [29 μs (19; 36 μs)], (p < 0.05). Blocking (NMJ failure) was higher in the CMT patients (13.4% (0.0; 90.9%)) vs. HC (0.0% (0.0; 4.5%)), (p < 0.05). In CMT, jitter and blocking correlated inversely with muscle strength, mobility, balance, and endurance. In CMT 1A and 2D mice, NMD670 increased both peak force and contractile endurance in vivo.

INTERPRETATION: Our study suggests that NMJ dysfunction contributes to muscle dysfunction in patients with CMT 1 and 2. Furthermore, our preclinical data provide proof-of-mechanism for recovery of muscle function with ClC-1 inhibition in CMT mouse models. Collectively, these findings suggest that targeting NMJ dysfunction with ClC-1 inhibitors could enhance muscle function in CMT patients, warranting further clinical trials.

Для цитирования: Grønnebæk Thomas Skjærlund, Haahr-Lillevang Helga, Skov Martin, Kelly Kristina, Kerr Nathan R, Viteri Jose A, Jaworek Andrea, Bartlett Amy, Bold Jane, Hutchison John, Quiroz Jorge, Tankisi Hatice, Pedersen Thomas Holm, Andersen Henning, Arnold William David. Neuromuscular transmission deficits in patients with CMT and ClC-1 inhibition in CMT animal models.. Annals of clinical and translational neurology. 2024. DOI: 10.1002/acn3.52252.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.